Global Osteomyelitis Market, By Type (Medullary Osteomyelitis, Superficial Osteomyelitis, Others), Treatment (Antibiotics, Surgery, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Osteomyelitis Market Analysis and Size
The global osteomyelitis market is expected to witness significant growth during the forecast period. As per the records of NCBI in 2016, the total annual incidence rate of osteomyelitis was 13 per 100,000 (acute osteomyelitis eight and subacute osteomyelitis five per 100,000) worldwide. In addition to this, the surgery segment is projected to grow at a CAGR of 6.7% in the previously mentioned forecast period. The enormous number of disposable and reusable electrosurgical tools accounts for this segment's considerable proportion.
Data Bridge Market Research analyses a growth rate in the global osteomyelitis market in the forecast period 2022-2029. The expected CAGR of global osteomyelitis market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 0.89 billion in 2021, and it would grow upto USD 1.59 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Osteomyelitis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Medullary Osteomyelitis, Superficial Osteomyelitis, Others), Treatment (Antibiotics, Surgery, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Akorn Incorporated (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Koninklijke Philips N.V. (Netherlands), General Electric (U.S.), Siemens Healthcare GmbH (U.S.), Shimadzu Corporation (Japan), GeneDx, LLC (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Osteomyelitis is a type of bone infection that can rise from the bacteria circulating in the bloodstream. It is mainly caused by staphylococcus aureus but another organism is linked to the age of the patient and predisposing conditions. The patient suffering from this disease often experienced pain, fever, and chills.
Global Osteomyelitis Market Dynamics
Drivers
- Rising Demand of Multi-Dimensional Therapies
Several benefits associated with minimally invasive treatments over standard treatment techniques boost the market growth. The benefits of minimally invasive treatments include less operating problems, reduced hospitalization, smaller and more aesthetic incisions, less discomfort, decreased infection risk, reduced postoperative care, and faster recovery. Additionally, advanced technology is used in minimally invasive treatments to detect and treat several disorders, including cancer. This factor boosts the opportunity of the osteomyelitis market.
- Rising Prevalence of Osteomyelitis
According to the records of NCBI, the total annual incidence rate of osteomyelitis was 13 per 100,000 in 2016 globally. The annual occurrence of pediatric osteomyelitis is around 13 per 100,000 individuals. The annual incidence in adult osteomyelitis is about 90 per 100,000 individuals. The market will witness huge demand for treatments as the prevalence is increasing thus, driving the global osteomyelitis market.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of drugs for osteomyelitis delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Growing Cases of Diabetes
According to the World Journal of Diabetes in 2017, diabetic patients are at a greater risk for osteomyelitis. In the recent, years, the occurrence of the osteomyelitis has increased. According to the American Diabetes Association in 2015, approximately 30.3 million Americans results for 9.4% of the population within the region had diabetes. The occurrence of diabetes is projected to boost the market.
Restraints/Challenges
- Impending Drug Approvals
Some many drugs or injections await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs
- Reimbursement Policies for the Disease
A major restraint is that medical reimbursement for osteomyelitis is limited. At a country level, medical reimbursement is one of the most important factors boosting the acceptance and demand of certain diagnostic or therapeutic goods among health care professionals and patients. In developed nations, the majority of healthcare insurance companies cover bone-related illnesses provided certain requirements are met. Osteomyelitis operations are neither covered nor reimbursed by many private insurance companies.
This global osteomyelitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global osteomyelitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Osteomyelitis Market Scope
The global osteomyelitis market is segmented on the basis of treatment, type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Antibiotics
- Surgery
- Others
Type
- Medullary Osteomyelitis
- Superficial Osteomyelitis
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Osteomyelitis Market Regional Analysis/Insights
The global osteomyelitis market is analyzed and market size insights and trends are provided by treatment, type, distribution channel and end-user as referenced above.
The major countries covered in the global osteomyelitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global osteomyelitis market throughout the forecasted period to the rise in cases of osteomyelitis and favourable government policies as well as advanced healthcare facilities.
North America dominates the market due to the rise in cases of osteomyelitis, favourable government policies, and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Osteomyelitis Market Share Analysis
The global osteomyelitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global osteomyelitis market.
Key players operating in the global osteomyelitis market include:
- Novartis AG (Switzerland)
- Fresenius Kabi AG (Germany)
- Akorn Incorporated (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Koninklijke Philips N.V. (Netherlands)
- General Electric (U.S.)
- Siemens Healthcare GmbH (U.S.)
- Shimadzu Corporation (Japan)
- GeneDx, LLC (U.S.)
SKU-